Zhejiang Huahai Raises $126 Million for New Production Facility
Published: May 03, 2013
by Richard Daverman, PhD
May 2, 2013 -- Zhejiang Huahai Pharma will offer 63.3 million shares at a price of 12.25 RMB each, raising 775 million RMB ($126 million) in a secondary offering. It will use the capital to build a new 1.5 billion RMB ($240 million) manufacturing facility for Diovan (valsartin) and other solid preparations for export. Diovan is an angiotensin receptor blocker that dilates blood vessels and is used to treat high blood pressure. More details....
Stock Symbol: (SHA: 600521)
Help employers find you! Check out all the jobs and post your resume.